Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7097)
All Articles published online
|
Publishing Process of This Article
|
Oct 7, 2021 (publication date) through Dec 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i37/6231.htm |
| Number | Citing Articles |
| 1 |
Steven Levitte. Point-of-Care Assays for Infliximab Therapeutic Drug Monitoring in Patients with IBD: Is Quicker Better?. Digestive Diseases and Sciences 2024; 69(1): 5 doi: 10.1007/s10620-023-08140-8
|
| 2 |
Karine Rodríguez-Fernández, Javier Zarzoso-Foj, Marina Saez-Bello, Almudena Mateu-Puchades, Antonio Martorell-Calatayud, Matilde Merino-Sanjuan, Elena Gras-Colomer, Monica Climente-Martí, Victor Mangas-Sanjuan. Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis. Pharmaceutics 2024; 16(10): 1295 doi: 10.3390/pharmaceutics16101295
|
| 3 |
Meng-Yao Wang, Jing-Wen Zhao, Chang-Qing Zheng, Li-Xuan Sang. Therapeutic drug monitoring in inflammatory bowel disease treatments. World Journal of Gastroenterology 2022; 28(15): 1604-1607 doi: 10.3748/wjg.v28.i15.1604
|
| 4 |
A.N. Tarashchuk, M.E. Zharova, I.O. Ivanikov. Maintenance immunosuppressive therapy for Crohn’s disease: patient adherence and its impact on treatment efficacy. Case report. Russian Journal of Evidence-Based Gastroenterology 2024; 13(2): 90 doi: 10.17116/dokgastro20241302190
|
| 5 |
Alina Ecaterina Jucan, Otilia Gavrilescu, Mihaela Dranga, Iolanda Valentina Popa, Ioana-Ruxandra Mihai, Vasile-Claudiu Mihai, Gabriela Stefanescu, Vasile Liviu Drug, Cristina Cijevschi Prelipcean, Radu-Alexandru Vulpoi, Oana-Bogdana Barboi, Irina Ciortescu, Catalina Mihai. Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing. Biomedicines 2023; 11(11): 3090 doi: 10.3390/biomedicines11113090
|
| 6 |
Reem Al-jabri, Panu Wetwittayakhlang, Peter L. Lakatos. Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities. Journal of Clinical Medicine 2023; 12(23): 7343 doi: 10.3390/jcm12237343
|
| 7 |
Livia Lontai, Lorant Gonczi, Fruzsina Balogh, Nora Komlodi, Tamas Resal, Klaudia Farkas, Tamas Molnar, Pal Miheller, Petra A. Golovics, Eszter Schafer, Tamas Szamosi, Akos Ilias, Peter L. Lakatos. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study. Digestive and Liver Disease 2022; 54(12): 1639 doi: 10.1016/j.dld.2022.07.004
|
| 8 |
Mahmoud E. Kamal, Rehab H. Werida, Mahasen A. Radwan, Safaa R. Askar, Gamal A. Omran, Marwa A. El-Mohamdy, Radwa S. Hagag. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. Inflammopharmacology 2024; 32(5): 3259 doi: 10.1007/s10787-024-01508-w
|
| 9 |
Brindusa Truta. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place. World Journal of Gastroenterology 2022; 28(13): 1380-1383 doi: 10.3748/wjg.v28.i13.1380
|
| 10 |
Hussein Hazim Saleh, Dheyaa Jabbar Khadim , Raghad Jawad Hussein. Correlation between Therapeutic Drug Monitoring of Infliximab Serum Trough Levels and other Biomarkers in Iraqi Patients with Crohn's Disease. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) 2024; 6(1): 239 doi: 10.54133/ajms.v6i1.606
|
| 11 |
Joseph William Clinton, Raymond Keith Cross. Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions. Clinical and Experimental Gastroenterology 2023; : 249 doi: 10.2147/CEG.S360248
|
| 12 |
Rachel Levy, Manar Matar, Maya Zvuloni, Raanan Shamir, Amit Assa. Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment: A Pharmacokinetic Model. Journal of Pediatric Gastroenterology & Nutrition 2023; 76(5): 576 doi: 10.1097/MPG.0000000000003726
|
| 13 |
Krishneel Dutt, Abhinav Vasudevan. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. Medicina 2024; 60(2): 250 doi: 10.3390/medicina60020250
|
| 14 |
Rachel C. Cogan, Basem W. El-Matary, Wael M. El-Matary. Therapeutic drug monitoring for biological medications in inflammatory bowel disease. Saudi Journal of Gastroenterology 2022; 28(5): 322 doi: 10.4103/sjg.sjg_3_22
|
| 15 |
Vlasta Oršić Frič, Vladimir Borzan, Ines Šahinović, Andrej Borzan, Sven Kurbel. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience. Pharmaceuticals 2023; 16(2): 239 doi: 10.3390/ph16020239
|